Full clinical trial not needed for Parkinson’s drug patent, IP Australia says

Intellectual Property 2022-05-24 12:32 pm By Sam Matthews | Melbourne

An IP Australia delegate has rejected German drug maker Ever Neuro Pharma’s claim that extensive experimental evidence was needed to prove the usefulness of a Parkinson’s drug developed by UK-based Britannia Pharmaceuticals.